China Health Industries Holdings, Inc. Reports Earnings Results for the Full Year Ended June 30, 2019
September 11, 2019 at 03:11 pm EDT
Share
China Health Industries Holdings, Inc. announced earnings results for the full year ended June 30, 2019. For the full year, the company announced sales was USD 9.275 million compared to USD 6.554 million a year ago. Operating income was USD 4.561 million compared to operating loss of USD 466,858 a year ago. Net income was USD 3.307 million compared to net loss of USD 316,827 a year ago.
China Health Industries Holdings, Inc. is a manufacturer of health food products. The Company's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The Company has three operating segments: Humankind, HLJ Huimeijia and others. Humankind is engaged in the manufacturing and sale of health products. HLJ Huimeijia is engaged in the manufacturing and distribution of tincture; ointments; rubber paste, including hormones; topical solution, suppositories, liniment, including traditional Chinese medicine extractions; enemas, and oral liquids. As of June 30, 2016, the Company, through Humankind manufactured and sold 14 health supplement products. As of June 30, 2016, the Company, through HLJ Huimeijia manufactured and sold 21 products. The Company's products are sold through sales agents.
CHINA HEALTH INDUSTRIES HOLDINGS, INC. 